Literature DB >> 22916841

Intermittent HIV-1 viremia (blips) and virological failure in a cohort of people living with HIV from São Paulo, Brazil.

Karim Yaqub Ibrahim1, Patricia Recordon-Pinson, Denis Malvy, Hervé Fleury, Aluisio Cotrim Segurado.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22916841      PMCID： PMC3426194          DOI： 10.1089/apc.2012.0199

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN： 1087-2914            Impact factor:   5.078


× No keyword cloud information.
  12 in total

1.  Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?

Authors:  Antonia L Moore; Mike Youle; Marc Lipman; Alessandro Cozzi-Lepri; Fiona Lampe; Sarah Madge; Shrenee Nesaratnam; Mervyn Tyrer; Zoe Cuthbertson; Darren Ransom; Clive Loveday; Margaret A Johnson; Andrew N Phillips
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

2.  Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

Authors:  Gilbert Greub; Alessandro Cozzi-Lepri; Bruno Ledergerber; Schlomo Staszewski; Luc Perrin; Veronica Miller; Patrick Francioli; Hansjakob Furrer; Manuel Battegay; Pietro Vernazza; Enos Bernasconi; Huldrych F Günthard; Bernard Hirschel; Andrew N Phillips; Amalio Telenti
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

Review 3.  2011 update of the drug resistance mutations in HIV-1.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Günthard; Roger Paredes; Deenan Pillay; Robert Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2011-11

4.  Prevalence and predictive value of intermittent viremia with combination hiv therapy.

Authors:  D V Havlir; R Bassett; D Levitan; P Gilbert; P Tebas; A C Collier; M S Hirsch; C Ignacio; J Condra; H F Günthard; D D Richman; J K Wong
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

5.  Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.

Authors:  Bernard Masquelier; Edwige Pereira; Gilles Peytavin; Diane Descamps; Jacques Reynes; Renaud Verdon; Hervé Fleury; R Garraffo; Geneviève Chêne; François Raffi; F Brun-Vézinet
Journal:  J Clin Virol       Date:  2005-05       Impact factor: 3.168

6.  Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.

Authors:  Somnuek Sungkanuparph; E Turner Overton; Warren Seyfried; Richard K Groger; Victoria J Fraser; William G Powderly
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

7.  Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification.

Authors:  Peter A Sklar; Douglas J Ward; Rose K Baker; Kathleen C Wood; Zarina Gafoor; Carlos F Alzola; Anne C Moorman; Scott D Holmberg
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

8.  Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.

Authors:  Juan Macias; José C Palomares; José A Mira; María J Torres; José A García-García; José M Rodríquez; Salvador Vergera; Juan A Pineda
Journal:  J Infect       Date:  2005-01-12       Impact factor: 6.072

9.  HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy.

Authors:  S C Kalichman; D Rompa
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

10.  Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus.

Authors:  Christian B Willberg; J Jeff McConnell; Emily M Eriksson; Larry A Bragg; Vanessa A York; Teri J Liegler; Fredrick M Hecht; Robert M Grant; Douglas F Nixon
Journal:  PLoS Pathog       Date:  2008-10-24       Impact factor: 6.823
View more
  3 in total

1.  The association of clinical follow-up intervals in HIV-infected persons with viral suppression on subsequent viral suppression.

Authors:  April Buscher; Michael Mugavero; Andrew O Westfall; Jeanne Keruly; Richard Moore; Mari-Lynn Drainoni; Meg Sullivan; Tracey E Wilson; Allan Rodriguez; Lisa Metsch; Lytt Gardner; Gary Marks; Faye Malitz; Thomas P Giordano
Journal:  AIDS Patient Care STDS       Date:  2013-07-26       Impact factor: 5.078

2.  Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.

Authors:  Laura Marije Hofstra; Tania Mudrikova; Arjen J Stam; Sigrid Otto; Kiki Tesselaar; Monique Nijhuis; Annemarie M J Wensing
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

Review 3.  HIV: how to manage low-level viraemia in people living with HIV.

Authors:  Emily K Hanners; Jessica Benitez-Burke; Melissa E Badowski
Journal:  Drugs Context       Date:  2022-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.